Return to Home Incidence > Table

Incidence Rates Table

Data Options

Incidence Rate Report by State

Kidney & Renal Pelvis (Late Stage^), 2016-2020

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by Rate
State
 sort alphabetically by name ascending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate descending
CI*Rank⋔
(95% Confidence Interval)
 sort by CI rank descending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late descending
US (SEER+NPCR) 1 4.8 (4.7, 4.8) N/A 18,519 28.3
Puerto Rico 6 2.0 (1.8, 2.2) N/A 84 23.4
District of Columbia 6 3.2 (2.6, 3.9) 49 (42, 49) 23 28.0
Colorado 6 3.8 (3.6, 4.1) 48 (42, 49) 248 27.0
Maryland 6 3.9 (3.7, 4.1) 47 (41, 49) 287 25.2
Virginia 6 3.9 (3.8, 4.1) 46 (41, 49) 406 25.3
Delaware 6 4.1 (3.6, 4.6) 45 (24, 49) 54 25.3
Florida 6 4.1 (4.0, 4.2) 44 (40, 47) 1,237 27.8
Arizona 6 4.2 (4.0, 4.4) 43 (36, 47) 377 26.9
Utah 3 4.2 (3.9, 4.6) 42 (26, 48) 119 28.1
Hawaii 3 4.3 (3.8, 4.7) 41 (23, 48) 79 32.1
Oregon 6 4.3 (4.1, 4.6) 40 (26, 46) 234 28.3
Alabama 6 4.4 (4.2, 4.7) 39 (25, 44) 275 24.6
California 3 4.4 (4.3, 4.5) 38 (31, 42) 1,977 30.1
New Hampshire 6 4.5 (4.0, 4.9) 37 (18, 48) 85 27.7
Massachusetts 3 4.5 (4.3, 4.7) 36 (24, 42) 389 29.5
Connecticut 3 4.5 (4.2, 4.8) 35 (22, 44) 210 29.1
South Carolina 6 4.6 (4.3, 4.8) 34 (23, 43) 301 26.6
New Jersey 3 4.6 (4.4, 4.8) 33 (24, 41) 510 28.6
New York 3 4.6 (4.5, 4.7) 32 (24, 40) 1,113 27.5
Pennsylvania 6 4.6 (4.5, 4.8) 31 (24, 40) 788 27.6
Michigan 6 4.6 (4.4, 4.8) 30 (23, 41) 594 28.9
Washington 5 4.6 (4.4, 4.8) 29 (23, 41) 414 30.4
Idaho 3 4.7 (4.3, 5.1) 28 (14, 45) 97 26.8
Montana 6 4.7 (4.2, 5.3) 27 (8, 46) 67 28.3
North Carolina 6 4.8 (4.6, 5.0) 26 (20, 35) 619 26.6
North Dakota 6 5.0 (4.3, 5.7) 25 (3, 46) 45 27.7
Tennessee 6 5.0 (4.8, 5.2) 24 (13, 29) 427 25.6
South Dakota 6 5.0 (4.4, 5.7) 23 (3, 43) 56 29.5
Nebraska 6 5.1 (4.7, 5.5) 22 (5, 37) 116 28.4
Wyoming 6 5.1 (4.4, 5.9) 21 (1, 45) 38 33.8
Kansas 6 5.2 (4.8, 5.5) 20 (5, 30) 179 26.9
Alaska 6 5.2 (4.5, 6.0) 19 (1, 44) 40 28.6
Ohio 6 5.2 (5.0, 5.4) 18 (10, 25) 777 30.3
Georgia 3 5.2 (5.0, 5.4) 17 (9, 25) 617 29.9
Maine 6 5.3 (4.8, 5.8) 16 (2, 32) 106 31.8
Vermont 6 5.3 (4.6, 6.1) 15 (1, 41) 46 33.1
Minnesota 6 5.3 (5.0, 5.6) 14 (5, 25) 363 30.5
Illinois 3 5.3 (5.1, 5.5) 13 (7, 23) 812 29.5
Rhode Island 6 5.4 (4.8, 6.0) 12 (1, 34) 73 32.8
New Mexico 3 5.4 (5.0, 5.9) 11 (2, 26) 144 34.9
Mississippi 6 5.4 (5.1, 5.8) 10 (2, 24) 199 25.3
Arkansas 6 5.5 (5.1, 5.8) 9 (2, 24) 206 25.5
Texas 3 5.5 (5.4, 5.6) 8 (4, 16) 1,634 27.9
Wisconsin 6 5.6 (5.3, 5.8) 7 (3, 19) 421 30.0
Missouri 6 5.6 (5.4, 5.9) 6 (2, 17) 436 29.5
Oklahoma 6 5.7 (5.3, 6.0) 5 (1, 19) 267 28.0
Kentucky 3 5.8 (5.6, 6.1) 4 (1, 13) 326 28.4
West Virginia 6 5.9 (5.5, 6.4) 3 (1, 18) 150 29.3
Iowa 3 6.1 (5.7, 6.4) 2 (1, 9) 248 31.5
Louisiana 3 6.2 (5.9, 6.5) 1 (1, 6) 346 27.6
Indiana 6
data not available
N/A
data not available
data not available
Nevada 6
data not available
N/A
data not available
data not available
Notes:
Created by statecancerprofiles.cancer.gov on 07/21/2024 7:13 am.

State Cancer Registries may provide more current or more local data.
Trend
Rising when 95% confidence interval of average annual percent change is above 0.
Stable when 95% confidence interval of average annual percent change includes 0.
Falling when 95% confidence interval of average annual percent change is below 0.

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

Data not available for this combination of data selections.

1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.
3 Source: SEER November 2022 submission. State Cancer Registry also receives funding from CDC's National Program of Cancer Registries.
5 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.
6 Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).
Data not available for this combination of geography, cancer site, age, and race/ethnicity.

Data for the United States does not include data from Nevada.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.

Return to Top